News & Updates

Renal denervation yields substantial reductions in ambulatory systolic blood pressure for up to 36 years in randomized controlled trials and up to 10 years in observational cohort studies without compromising renal function, according to the results of a systematic review and meta-analysis.

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Very elderly patients with nonvalvular atrial fibrillation fare well with either edoxaban or apixaban in terms of stroke prevention, although those on edoxaban may have higher bleeding risk, according to a study.

People who refused to be vaccinated against COVID-19 appear to be at significantly greater risks of a traffic accident, reports a study.

Pregnant women who are being treated with ustekinumab or vedolizumab appear to experience no greater complications as those receiving antitumour necrosis factor (anti-TNF) agents, immunomodulators, or combination anti-TNF/immunomodulators, according to a study.

Use of either adalimumab or infliximab as first antitumour necrosis factor (anti-TNF) agent results in positive outcomes among children with Crohn’s disease (CD), a study has shown.

Morphine appears to effectively palliate cough in patients with idiopathic pulmonary fibrosis (IPF), findings from the phase II PACIFY COUGH crossover trial suggest.

Treatment with upadacitinib, an oral selective Janus kinase inhibitor, led to greater proportions of days spent with improved nighttime itch and sleep disturbance experienced by patients with moderate-to-severe atopic dermatitis (AD), according to an integrated analysis of the phase III Measure Up 1 and 2 studies presented at AAD 2024.